You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦製藥(03933.HK):集團產品注射用頭孢曲鬆鈉通過一致性評價
格隆匯 03-07 17:58

格隆匯3月7日丨聯邦製藥(03933.HK)公告,公司全資附屬公司珠海聯邦製藥股份有限公司中山分公司申報的注射用頭孢曲鬆鈉(規格:1.0g;2.0g)經中國國家藥品監督管理局審批,通過仿製藥質量和療效一致性評價("一致性評價")。

注射用頭孢曲鬆鈉是第三代頭孢菌素類抗生素,臨牀適用於治療敏感致病菌引起的呼吸道感染、腹部感染、腎臟及泌尿道感染、生殖系統感染等,以及術前預防感染。其臨牀應用廣泛,療效顯著,具有抗菌譜廣、組織穿透性強、半衰期長、毒副反應低等優勢。現時,注射用頭孢曲鬆鈉爲國家基藥目錄(二零一八年版)及國家醫保目錄(2024年版)甲類藥品。

本次獲批將進一步有助於公司鞏固於抗感染領域的優勢地位。公司將持續致力於新產品研發及推進一致性評價,預期將爲公司及其股東創造更大收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account